BioConnection, an independent CDMO based in The Netherlands, specialized in GMP-certified manufacturing of sterile drug products in vials and syringes, has announced that Nykode Therapeutics AS, (formerly Vaccibody), selected BioConnection for the aseptic drug product manufacturing of its lead vaccine candidate.
 
Nykode Therapeutics is a clinical stage biotechnology company, developing vaccines and novel immunotherapies for the treatment of cancer and infectious diseases with a high unmet medical need.
 
Mette Husbyn, CTO of Nykode, said, “We chose to partner with BioConnection for the manufacturing of Nykode’s precious clinical trial material because of their tailored solutions for production, matching the requirements for small scale batches. Moreover, BioConnection has an excellent broad manufacturing and regulatory track record, including EMA and FDA certification.”
 
BioConnection’s CEO Alexander Willemse added, “Phase I trials usually require small batches of drug products that have to be delivered in a precise manner. Capitalizing on our years of experience, we offer automated filling in large volumes up to 40 million vials per year, and importantly also manual fill and finish. I’m very happy that our manufacturing capabilities, perfectly match Nykode’s exact early phase clinical trial needs.”